OBJECTIVES: This study assessed the outcomes of combination therapy including rituximab for antibody-mediated rejection after lung transplantation. METHODS: Retrospective chart reviews were performed for all patients who received combination therapy including rituximab for post-lung transplantation antibody-mediated rejection between June 2008 and October 2018. RESULTS: Among the 196 consecutive patients undergoing lung transplantation during the study period, eight (4.1%) were eligible for this study. Two patients (25.0%) were classified as having clinically definite antibody-mediated rejection and six (75.0%) as having possible antibody-mediated rejection. Prior to treatment, four patients (50.0%) met the definition of chronic lung allograft dysfunction; seven of the eight patients (87.5%) remained alive at 6 months and four (50.0%) at 12 months after antibody-mediated rejection. All patients identified as having chronic lung allograft dysfunction, prior to the treatment, died of allograft failure, or underwent re-transplantation. Decreases in the mean fluorescence intensities of the major donor-specific antibodies were observed in three patients. One patient, diagnosed with clinical antibody-mediated rejection but without pre-treatment chronic lung allograft dysfunction, began treatment relatively soon after lung transplantation, and demonstrated improved respiratory function at the 3-year follow-up. CONCLUSIONS: Our experience suggests that multimodality therapy that includes rituximab is feasible and may prevent progression of antibody-mediated rejection after lung transplantation in selected patients.
OBJECTIVES: This study assessed the outcomes of combination therapy including rituximab for antibody-mediated rejection after lung transplantation. METHODS: Retrospective chart reviews were performed for all patients who received combination therapy including rituximab for post-lung transplantation antibody-mediated rejection between June 2008 and October 2018. RESULTS: Among the 196 consecutive patients undergoing lung transplantation during the study period, eight (4.1%) were eligible for this study. Two patients (25.0%) were classified as having clinically definite antibody-mediated rejection and six (75.0%) as having possible antibody-mediated rejection. Prior to treatment, four patients (50.0%) met the definition of chronic lung allograft dysfunction; seven of the eight patients (87.5%) remained alive at 6 months and four (50.0%) at 12 months after antibody-mediated rejection. All patients identified as having chronic lung allograft dysfunction, prior to the treatment, died of allograft failure, or underwent re-transplantation. Decreases in the mean fluorescence intensities of the major donor-specific antibodies were observed in three patients. One patient, diagnosed with clinical antibody-mediated rejection but without pre-treatment chronic lung allograft dysfunction, began treatment relatively soon after lung transplantation, and demonstrated improved respiratory function at the 3-year follow-up. CONCLUSIONS: Our experience suggests that multimodality therapy that includes rituximab is feasible and may prevent progression of antibody-mediated rejection after lung transplantation in selected patients.
Authors: M S Czuczman; A J Grillo-López; C A White; M Saleh; L Gordon; A F LoBuglio; C Jonas; D Klippenstein; B Dallaire; C Varns Journal: J Clin Oncol Date: 1999-01 Impact factor: 44.544
Authors: A J Demetris; C Bellamy; S G Hübscher; J O'Leary; P S Randhawa; S Feng; D Neil; R B Colvin; G McCaughan; J J Fung; A Del Bello; F P Reinholt; H Haga; O Adeyi; A J Czaja; T Schiano; M I Fiel; M L Smith; M Sebagh; R Y Tanigawa; F Yilmaz; G Alexander; L Baiocchi; M Balasubramanian; I Batal; A K Bhan; J Bucuvalas; C T S Cerski; F Charlotte; M E de Vera; M ElMonayeri; P Fontes; E E Furth; A S H Gouw; S Hafezi-Bakhtiari; J Hart; E Honsova; W Ismail; T Itoh; N C Jhala; U Khettry; G B Klintmalm; S Knechtle; T Koshiba; T Kozlowski; C R Lassman; J Lerut; J Levitsky; L Licini; R Liotta; G Mazariegos; M I Minervini; J Misdraji; T Mohanakumar; J Mölne; I Nasser; J Neuberger; M O'Neil; O Pappo; L Petrovic; P Ruiz; Ö Sağol; A Sanchez Fueyo; E Sasatomi; A Shaked; M Shiller; T Shimizu; B Sis; A Sonzogni; H L Stevenson; S N Thung; G Tisone; A C Tsamandas; A Wernerson; T Wu; A Zeevi; Y Zen Journal: Am J Transplant Date: 2016-07-14 Impact factor: 8.086
Authors: Gastón J Piñeiro; Erika De Sousa-Amorim; Manel Solé; José Ríos; Miguel Lozano; Frederic Cofán; Pedro Ventura-Aguiar; David Cucchiari; Ignacio Revuelta; Joan Cid; Eduard Palou; Josep M Campistol; Federico Oppenheimer; Jordi Rovira; Fritz Diekmann Journal: BMC Nephrol Date: 2018-10-11 Impact factor: 2.388
Authors: Allan R Glanville; Christian Benden; Anne Bergeron; Guang-Shing Cheng; Jens Gottlieb; Erika D Lease; Michael Perch; Jamie L Todd; Kirsten M Williams; Geert M Verleden Journal: ERJ Open Res Date: 2022-07-25